|
AU3733295A
|
|
Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
|
|
SG46620A1
|
|
Method and composition foor the treatment of autoimmune hepatitis
|
|
PH30414A
|
|
Thymosin alpha-1 derivatives
|
|
JPH06279309A
|
|
Treatment agent of c type hepatitis for interferon treatment nonresponse person
|
|
NZ258326A
|
|
The use, in the preparation of a medicament, of thymosin alpha 1 for treatment of patients having decompensated liver disease
|
|
SG64899A1
|
|
Method and composition for treatment of patients having decompsated liver disease
|
|
US5750501A
|
|
Method and composition for treatment of patients having decompensated liver disease
|
|
AU5592094A
|
|
Method and composition for treatment of patients having decompensated liver disease
|
|
EP0731710A1
|
|
Thymosine alpha 1 containing compositions for the treatment of patients having decompensated liver disease
|
|
EP0603305A1
|
|
Use of a thymosin in the treatment of hepatitis c
|
|
IL97297D0
|
|
Solid phase process for synthesizing peptides
|
|
EP0341935A2
|
|
A solid phase process for synthesizing Thymosin alpha 1
|
|
IL97297A
|
|
Solid phase process for synthesizing peptides
|
|
IL78479D0
|
|
Solid phase process for synthesizing peptides
|
|
US4855407A
|
|
Solid phase process for synthesizing peptides
|
